Shares of Harmony Biosciences Holdings, Inc. fell 7% on October 22 during closing arguments in a patent dispute over its drug Wakix. The legal battle is part of an ANDA patent litigation case against AET Pharma, taking place in Wilmington, Delaware. This dispute could impact Harmony's market position and future sales of Wakix depending on the court's decision.
Harmony Biosciences shares are in focus amid a patent dispute over Wakix. For readers following cryptocurrency markets, here is Pluang's snapshot as of Oct 23, 2026 20:03 WIB: out of 50 major cryptocurrencies, 29 rose and 20 fell. Notable movers include BAL at Rp16.297 with an 11.14% gain, EOS at Rp12.649 up 8.13%, and COTI at Rp211 rising 6.61% despite a 62% sell order activity.
Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...
Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...
Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...
ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...
eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...
